Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

ATXS

Astria Therapeutics Inc

Last Close
Apr 24 • 04:00PM ET
9.00
Dollar change
-0.64
Percentage change
-6.64 		%
Held by: VTI IWM VXF IWO VTWO DWAS LABU IWC PTH ITOT Scroll to Statements
IndexRUT P/E- EPS (ttm)-2.34 Insider Own18.84% Shs Outstand54.90M Perf Week-14.69%
Market Cap494.10M Forward P/E- EPS next Y-1.90 Insider Trans44.83% Shs Float44.56M Perf Month-38.98%
Income-72.89M PEG- EPS next Q-0.34 Inst Own69.24% Short Float11.35% Perf Quarter5.88%
Sales0.00M P/S- EPS this Y35.19% Inst Trans13.24% Short Ratio4.79 Perf Half Y91.90%
Book/sh3.60 P/B2.50 EPS next Y-20.83% ROA-30.04% Short Interest5.06M Perf Year-26.59%
Cash/sh4.49 P/C2.00 EPS next 5Y- ROE-31.40% 52W Range4.26 - 16.90 Perf YTD17.19%
Dividend Est.- P/FCF- EPS past 5Y39.84% ROI-29.98% 52W High-46.75% Beta0.79
Dividend TTM- Quick Ratio21.73 Sales past 5Y0.00% Gross Margin- 52W Low111.27% ATR (14)0.86
Dividend Ex-Date- Current Ratio21.73 EPS Y/Y TTM35.59% Oper. Margin0.00% RSI (14)24.16 Volatility7.17% 6.95%
Employees59 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price25.57
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q-19.43% Payout- Rel Volume0.62 Prev Close9.64
Sales Surprise- EPS Surprise-10.26% Sales Q/Q- EarningsMar 04 AMC Avg Volume1.06M Price9.00
SMA20-22.02% SMA50-32.50% SMA200-0.05% Trades Volume659,022 Change-6.64%
Date Action Analyst Rating Change Price Target Change
Mar-28-23Initiated Evercore ISI Outperform $18
Apr-09-24 08:00AM
Astria Therapeutics Appoints Sunil Agarwal to Its Board of Directors
(Business Wire)
Apr-03-24 07:00PM
Chief Medical Officer Christopher Morabito Sells 10,000 Shares of Astria Therapeutics Inc (ATXS)
(GuruFocus.com) -5.47%
04:10PM
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire)
Mar-25-24 07:30AM
Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE
(Business Wire)
Mar-05-24 04:10PM
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire)
10:52PM Loading…
Mar-04-24 10:52PM
ATXS Stock Earnings: Astria Therapeutics Misses EPS for Q4 2023
(InvestorPlace)
04:10PM
Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
(Business Wire)
Feb-29-24 03:02AM
14 Stocks With Heavy Insider Buying In 2024
(Insider Monkey)
Feb-20-24 08:00AM
Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma & Immunology Annual Meeting
(Business Wire)
Feb-06-24 08:00AM
Astria Therapeutics to Present at Upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference
(Business Wire) +6.25%
Feb-05-24 04:00PM
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire) +6.95%
Jan-30-24 07:29PM
Chief Medical Officer Christopher Morabito Sells 10,000 Shares of Astria Therapeutics Inc
(GuruFocus.com) +6.62%
09:08AM
Astria Therapeutics Announces Pricing of $125 Million Underwritten Offering
(Business Wire)
Dec-04-23 04:00PM
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire)
Nov-27-23 08:00AM
Astria Therapeutics to Present STAR-0215 Data at the 2023 World Allergy Congress
(Business Wire)
08:00AM Loading…
Nov-21-23 08:00AM
Astria Therapeutics to Present at Upcoming 6th Annual Evercore ISI HealthCONx Conference
(Business Wire)
Nov-14-23 01:07PM
Astria Therapeutics, Inc. (NASDAQ:ATXS) Q3 2023 Earnings Call Transcript
(Insider Monkey)
Nov-13-23 11:07AM
Astria Therapeutics Inc (ATXS) Reports Q3 Financial Results and Corporate Developments
(GuruFocus.com)
08:00AM
Astria Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update
(Business Wire)
Nov-10-23 08:00AM
Astria Therapeutics Presents New Phase 1a Data Confirming Potential for STAR-0125 to Prevent Hereditary Angioedema Attacks with Dosing 2 or 4 Times Per Year at the 2023 American College of Allergy, Asthma, and Immunology Annual Scientific Meeting
(Business Wire)
Nov-09-23 08:00AM
Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference
(Business Wire)
Nov-03-23 08:10AM
Astria Therapeutics to Present New STAR-0215 Data at the 2023 American College of Allergy, Asthma, And Immunology Annual Scientific Meeting
(Business Wire)
Nov-02-23 04:00PM
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire)
Oct-30-23 08:00AM
Astria Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on Monday, November 13th
(Business Wire)
Oct-11-23 07:14PM
Astria Therapeutics Announces Pricing of $64 Million Underwritten Offering
(Business Wire)
05:10PM
Astria Therapeutics Announces Exclusive Worldwide License Agreement with Ichnos Sciences for OX40 Portfolio
(Business Wire)
Oct-03-23 04:00PM
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire)
Sep-06-23 08:00AM
Astria Therapeutics to Participate in Upcoming Investor Conferences
(Business Wire)
Aug-31-23 08:00AM
Astria Therapeutics Announces Publication of STAR-0215 Preclinical Data in the Journal of Pharmacology and Experimental Therapeutics
(Business Wire)
Aug-30-23 10:01AM
2 Strong Buy Stocks Under $10 That Oppenheimer Sees Surging Over 200% Heres Why They Could Jump
(TipRanks)
08:00AM Loading…
Aug-25-23 08:00AM
Astria Therapeutics to Present Patient Survey Data at Upcoming 2023 HAEi Regional EMEA Conference
(Business Wire)
Aug-07-23 04:10PM
Astria Therapeutics Reports Second Quarter Financial Results and Provides a Corporate Update
(Business Wire)
Aug-02-23 04:00PM
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire)
Jul-20-23 08:00AM
Astria Therapeutics Receives Fast Track Designation for STAR-0215 for the Treatment of Hereditary Angioedema
(Business Wire)
Jul-17-23 08:00AM
Astria Therapeutics Names John Ruesch as Senior Vice President, Pharmaceutical Sciences and Technical Operations
(Business Wire)
Jul-14-23 08:00AM
Astria Therapeutics to Present Patient Survey Data at Upcoming 2023 US HAEA National Summit
(Business Wire)
Jul-06-23 04:00PM
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire)
Jun-06-23 08:00AM
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire)
Jun-05-23 08:00AM
Astria Therapeutics to Present STAR-0215 at the 2023 European Academy of Allergy, Asthma, and Immunology Annual Meeting
(Business Wire) +5.55%
May-31-23 08:00AM
Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference
(Business Wire)
May-11-23 04:10PM
Astria Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update
(Business Wire)
May-02-23 04:00PM
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire) -5.17%
Apr-28-23 08:00AM
Astria Therapeutics to Present STAR-0215 at the 13th C1-Inhibitor Deficiency and Angioedema Workshop
(Business Wire) +8.03%
Apr-19-23 08:00AM
Astria Therapeutics Names Andrea Matthews Chief Business Officer
(Business Wire) +5.37%
Apr-04-23 04:00PM
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire) -5.88%
Mar-22-23 08:00AM
Astria Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update
(Business Wire)
Mar-08-23 08:00AM
Astria Therapeutics to Report Fourth Quarter/Full Year 2022 Financial Results and Recent Corporate Developments on Wednesday, March 22nd
(Business Wire)
Mar-06-23 08:00AM
Astria Therapeutics to Present at Upcoming Oppenheimer 33rd Annual Healthcare Conference
(Business Wire)
Mar-02-23 04:00PM
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire) +12.19%
Feb-24-23 08:00AM
Astria Therapeutics Presents Additional Data Supporting STAR-0215 Profile as a Long-Acting Preventative Therapy for Hereditary Angioedema at the 2023 American Academy of Allergy, Asthma, and Immunology Annual Meeting
(Business Wire)
Feb-21-23 08:00AM
Astria Therapeutics to Present New STAR-0215 Data at the 2023 American Academy of Allergy, Asthma, and Immunology Annual Meeting
(Business Wire) -5.83%
Feb-08-23 08:00AM
Astria Therapeutics Initiates ALPHA-STAR Phase 1b/2 Clinical Trial of STAR-0215 in People with HAE
(Business Wire) -6.83%
Feb-02-23 04:00PM
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire) +5.76%
Dec-19-22 04:01PM
Astria Therapeutics Announces Closing of Underwritten Offering and Full Exercise of Underwriters Option to Purchase Additional Shares
(Business Wire) -6.01%
Dec-15-22 06:10AM
Astria Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock
(Business Wire)
06:00AM
Astria Therapeutics Announces Positive Preliminary Results from the Phase 1a Clinical Trial of STAR-0215 in Healthy Subjects
(Business Wire)
Dec-02-22 04:00PM
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire)
Nov-10-22 04:10PM
Astria Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
(Business Wire)
Nov-09-22 08:00AM
Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference
(Business Wire) -5.37%
Nov-07-22 08:00AM
Astria Therapeutics to Present STAR-0215 Modeling and Simulation Data at the 2022 American College of Allergy, Asthma and Immunology Annual Meeting
(Business Wire) -9.94%
Nov-02-22 08:00AM
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire)
Sep-16-22 08:00AM
Astria Therapeutics to Host Virtual R&D Day: Update on STAR-0215 and Its Clinical Development
(Business Wire)
Sep-06-22 08:00AM
Astria Therapeutics to Present at Upcoming Investment Conferences
(Business Wire)
Sep-02-22 08:00AM
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire) +6.11%
Aug-09-22 04:32PM
Astria Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
(Business Wire)
Aug-04-22 08:00AM
Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0215, a Monoclonal Antibody Inhibitor of Plasma Kallikrein for Treatment of Hereditary Angioedema
(Business Wire)
Aug-03-22 08:00AM
Astria Therapeutics to Present at Upcoming Wedbush PacGrow Healthcare Conference 2022
(Business Wire) +6.91%
Aug-02-22 08:00AM
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire)
Jul-29-22 09:34AM
Here's Why We're Not Too Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Situation
(Simply Wall St.)
Jul-28-22 08:00AM
Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0215, a Monoclonal Antibody Inhibitor of Plasma Kallikrein for Treatment of Hereditary Angioedema
(Business Wire) +8.56%
Jul-15-22 08:00AM
Astria Therapeutics Names Chris Morabito Chief Medical Officer
(Business Wire) +6.84%
Jul-14-22 08:00AM
Astria Therapeutics to Participate in Virtual Fireside Chat at Upcoming H.C. Wainwright 1st Annual Hereditary Angioedema Conference
(Business Wire) -6.17%
Jul-05-22 08:00AM
Astria Therapeutics Presents New Preclinical Data Showing Differentiated Profile of STAR-0215, in Development for Treatment of Hereditary Angioedema
(Business Wire)
Jun-23-22 08:00AM
Astria Therapeutics to Present New Preclinical STAR-0215 Data at the European Academy of Allergy and Clinical Immunology 2022 Hybrid Congress
(Business Wire)
Jun-03-22 08:00AM
Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference
(Business Wire)
Jun-02-22 08:00AM
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire) -7.05%
May-12-22 04:10PM
Astria Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update
(Business Wire)
Apr-21-22 08:00AM
Astria Therapeutics to Present STAR-0215 Data at the 2022 Fc Receptor and IgG Targeted Therapies Conference
(Business Wire)
Apr-04-22 08:00AM
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire)
Mar-10-22 05:01PM
Astria Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update
(Business Wire) +6.41%
Mar-09-22 08:00AM
Astria Therapeutics to Participate in Upcoming Investor Conferences
(Business Wire) +6.68%
Feb-18-22 08:00AM
Astria Therapeutics to Present STAR-0215 Data at the 2022 American Academy of Allergy, Asthma and Immunology Annual Meeting
(Business Wire)
Nov-10-21 08:00AM
Astria Therapeutics Reports Third Quarter 2021 Financial Results and Provides a Corporate Update
(Business Wire)
Nov-09-21 08:00AM
Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference
(Business Wire)
Nov-05-21 08:00AM
Astria Therapeutics Presents New Preclinical Data Showing the Differentiated Profile of STAR-0215, in Development to Treat Hereditary Angioedema
(Business Wire)
Oct-27-21 08:00AM
Astria Therapeutics to Report Third Quarter 2021 Financial Results and Recent Corporate Developments on Wednesday, November 10
(Business Wire)
Oct-21-21 08:00AM
Astria Therapeutics to Present New STAR-0215 Preclinical Results at the 2021 American College of Allergy, Asthma and Immunology Annual Scientific Meeting
(Business Wire)
Oct-18-21 08:00AM
Astria Therapeutics Presents Findings on Burdens of Disease and Treatment in Hereditary Angioedema at the 2021 NORD Rare Diseases and Orphan Products Breakthrough Summit
(Business Wire) -7.54%
Oct-12-21 08:00AM
Astria Therapeutics to Present Findings on Burdens of Disease and Treatment in Hereditary Angioedema at the 2021 NORD Rare Diseases and Orphan Products Breakthrough Summit
(Business Wire)
Oct-03-21 09:52PM
3 Stocks That Could Double From Current Levels; Oppenheimer Says Buy
(TipRanks)
Sep-10-21 08:00AM
Astria Therapeutics to Present at Upcoming Investor Conferences
(Business Wire)
Astria Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is STAR-0215, which is intended to treat Hereditary Angioedema, a rare genetic disorder characterized by severe, recurrent, unpredictable, painful, and sometimes life-threatening swelling in the face, limbs, abdomen, and airway. The company was founded by Michael R. Jirousek, Jill C. Milne and Steven E. Shoelson on June 26, 2008 and is headquartered in Boston, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Morabito ChristopherChief Medical OfficerApr 01 '24Option Exercise3.8710,00038,70010,000Apr 03 04:05 PM
Morabito ChristopherChief Medical OfficerApr 01 '24Sale13.5910,000135,9390Apr 03 04:05 PM
PERCEPTIVE ADVISORS LLCDirectorFeb 01 '24Buy12.092,481,35029,999,5224,873,721Feb 05 05:02 PM
Morabito ChristopherChief Medical OfficerJan 29 '24Option Exercise3.879,20035,6049,200Jan 30 05:03 PM
Morabito ChristopherChief Medical OfficerJan 29 '24Sale11.159,200102,5520Jan 30 05:03 PM
Morabito ChristopherChief Medical OfficerJan 26 '24Option Exercise3.878003,096800Jan 30 05:03 PM
Morabito ChristopherChief Medical OfficerJan 26 '24Sale11.028008,8120Jan 30 05:03 PM
PERCEPTIVE ADVISORS LLCDirectorDec 21 '23Buy6.20740,0004,588,0002,392,371Dec 22 02:51 PM
PERCEPTIVE ADVISORS LLCDirectorOct 16 '23Buy6.511,074,6086,999,9971,652,371Oct 18 04:11 PM
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.